CAJ | 학술논문

目的探索血缘HLA全相合骨髓造血干细胞移植(HSCT)后复发病例进行同一供者外周血造血干细胞二次移植(HSCT2)的可行性.方法 1例急性髓系白血病(M4)患者接受血缘HLA全相合供者骨髓移植后18个月复发,染色体检查提示为受者复发型.给予CY-TBI预处理后输注同一供者外周血HSCT2,同时降低预防移植物抗宿主病(GVHD)强度.结果患者HSCT2后获得稳定植入,患者并发急性GVHD(肠道Ⅳ级,皮肤Ⅲ级),完全缓解至+8月.结论对于血缘造血干细胞供者移植后复发的患者,HSCT2同一供者HSCT是可行的.
목적 탐색혈연HLA전상합골수조혈간세포이식(HSCT)후복발병례진행동일공자외주혈조혈간세포이차이식(HSCT2)적가행성.방법 1례급성수계백혈병(M4)환자접수혈연HLA전상합공자골수이식후18개월복발,염색체검사제시위수자복발형.급여CY-TBI예처리후수주동일공자외주혈HSCT2,동시강저예방이식물항숙주병(GVHD)강도.결과 환자HSCT2후획득은정식입,환자병발급성GVHD(장도Ⅳ급,피부Ⅲ급),완전완해지+8월.결론 대우혈연조혈간세포공자이식후복발적환자,HSCT2동일공자HSCT시가행적.
Objective To evaluate the efficacy of second allogeneic hematopoietic stem cell transplantation (allo-HSCT) for treatment of leukemia relapsed after first allo-HSCT from one sibling donor.Methods One patient with acute myeloid leukemia (AML-M4) underwent sibling donor bone marrow transplant (conditioning regimens was Bu/Cy) and relapsed after 18 months. The patient received the same donor's peripheral blood stem cell (PBSC) for second transplantation after receiving CY-TBI regimens,and reduced intension of prophylaxis of GVHD. Results The patient achieved stable engraftment after second HSCT. The patients suffered acute GVHD (intestinal Ⅳ and cutaneous Ⅲ) and had been complete remission to +8 months. Conclusion Second related HSCT is feasible in relapsed patient who had undergone related allo-BMT.